Share price · AMRN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AMRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026+6.7%
- 8 Sep 2026+4.5%
Nothing announced by AMRN that day or the session before.
- 4 Jun 2026-5.0%
Nothing announced by AMRN that day or the session before.
- 10 Mar 2026+9.5%
Nothing announced by AMRN that day or the session before.
- 25 Feb 2026-9.5%
- 8 Jan 2026+16.9%
- 8 Dec 2025-9.8%
Nothing announced by AMRN that day or the session before.
Share of unusual movement by asset
For each asset, the share of AMRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Icosapent Ethyl(Vascepa) | Approved | Omega-3 fatty acid (EPA)Small molecule | Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $40M | $4.2M | $157M+ $167M short-term inv. | —$9.2M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $42M | $4.8M | $144M+ $171M short-term inv. | $7.7M$6.6M operating cash flow | report ↗ |
| 2026-Q1 | $45M | $4.7M | $131M+ $177M short-term inv. | $11M$6.4M operating cash flow | report ↗ |
| 2025-Q3 | $50M | $4.2M | $123M+ $164M short-term inv. | $7.7M-$13M operating cash flow | report ↗ |
| 2025-Q2 | $73M | $4.9M | $148M+ $151M short-term inv. | $14M$17M operating cash flow | report ↗ |
| 2025-Q1 | $42M | $5.3M | $120M+ $162M short-term inv. | $16M-$12M operating cash flow | report ↗ |
| 2024-Q3 | $42M | $4.5M | $157M+ $149M short-term inv. | $25M-$2.4M operating cash flow | report ↗ |
| 2024-Q2 | $67M | $4.8M | $216M+ $91M short-term inv. | —-$2.8M operating cash flow | report ↗ |
| 2024-Q1 | $57M | $5.6M | $214M+ $94M short-term inv. | $9.9M-$13M operating cash flow | report ↗ |
| 2023-Q3 | $66M | $5.1M | $271M+ $50M short-term inv. | $19M$7.3M operating cash flow | report ↗ |
| 2023-Q2 | $80M | $5.6M | $233M+ $80M short-term inv. | $18M$7.2M operating cash flow | report ↗ |
| 2023-Q1 | $86M | $5.7M | $191M+ $113M short-term inv. | $16M-$7.0M operating cash flow | report ↗ |
| 2022-Q3 | $90M | $5.8M | $241M+ $63M short-term inv. | $5.1M-$18M operating cash flow | report ↗ |
| 2022-Q2 | $94M | $9.4M | $228M+ $85M short-term inv. | $70M-$65M operating cash flow | report ↗ |
| 2022-Q1 | $95M | $10M | $219M+ $143M short-term inv. | $32M-$99M operating cash flow | report ↗ |
| 2021-Q3 | $142M | $7.8M | $223M+ $256M short-term inv. | $13M-$4.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $214M | $20M | $135M+ $168M short-term inv. | $9.7M$6.7M operating cash flow | report ↗ |
Amarin reported full-year 2025 revenue of $213.65M, down 6.5% YoY from $228.61M. R&D spend was $19.81M, down 5.1% YoY, and cash and equivalents totaled $134.66M, with a net loss of $38.8M.
The company highlighted a long-term license and supply agreement with Recordati to commercialize VAZKEPA across Europe, sustained U.S. market leadership for the VASCEPA franchise, and 45 publications supporting the product’s scientific evidence base. Management said restructuring initiatives had delivered $31M of an expected $70M in cost savings, with total restructuring costs projected at $37–$40M, and positioned the company to generate positive cash flow for the full year ahead.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $229M | $21M | $121M+ $173M short-term inv. | $21M-$31M operating cash flow | report ↗ |
| 2023-FY | $307M | $22M | $199M+ $121M short-term inv. | $15M$6.9M operating cash flow | report ↗ |
| 2022-FY | $369M | $30M | $218M+ $92M short-term inv. | $26M-$180M operating cash flow | report ↗ |
| 2021-FY | $583M | $29M | $219M+ $235M short-term inv. | —-$67M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-01 | Fishman Peter L. · SVP, CFO | Option exercise | 313 | — | — | Form 4 |
| 2026-08-01 | Fishman Peter L. · SVP, CFO | Tax withholding | 155 | $14.26 | $2K | Form 4 |
| 2026-08-01 | Fishman Peter L. · SVP, CFO | Award / grant (derivative) | 313 | — | — | Form 4 |
| 2026-07-01 | Provoost Jonathan · EVP, Chief Legal Officer | Option exercise | 3,688 | — | — | Form 4 |
| 2026-07-01 | Ketchum Steven B · EVP, Chief Scientific Officer | Option exercise | 3,688 | — | — | Form 4 |
| 2026-07-01 | Keenan David Paul · EVP, Chief Operating Officer | Option exercise | 3,688 | — | — | Form 4 |
| 2026-07-01 | Fishman Peter L. · SVP, CFO | Option exercise | 2,447 | — | — | Form 4 |
| 2026-07-01 | Provoost Jonathan · EVP, Chief Legal Officer | Tax withholding | 1,264 | $15.94 | $20K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 4.6M shares ($57.1M, 21.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Sarissa Capital Management LP | 1,673,395 | $24.2M |
| 2 | Kynam Capital Management, LP | 472,382 | $6.8M |
| 3 | MILLENNIUM MANAGEMENT LLC | 300,536 | $4.3M |
| 4 | MORGAN STANLEY | 293,172 | $4.2M |
| 5 | Point72 Asset Management, L.P. | 240,761 | $3.5M |
| 6 | Waterfront Wealth Inc. | 203,338 | $2.9M |
| 7 | Eversept Partners, LP | 147,715 | $2.1M |
| 8 | TWO SIGMA INVESTMENTS, LP | 107,542 | $1.6M |
| 9 | CITADEL ADVISORS LLC | 80,575 | $1.2M |
| 10 | BNP PARIBAS FINANCIAL MARKETS | 75,503 | $1.1M |
| 11 | LCM Capital Management Inc | 43,462 | $628K |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 37,667 | $545K |
| 13 | STATE STREET CORP | 24,949 | $361K |
| 14 | Bleakley Financial Group, LLC | 23,564 | $341K |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 19,256 | $278K |